These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 12426631

  • 21. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
    Martín M, Estornell J, Orero M, Pérez JL, Ridocci F, Martínez V.
    Rev Esp Cardiol; 2006 Jan; 59(1):75-7. PubMed ID: 16434009
    [Abstract] [Full Text] [Related]

  • 22. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E, Bianco I, Graziani B, Lerone M, Valente M, Congedo P, Ponzini D, Costantini S.
    Acta Haematol; 1982 Jan; 68(2):115-23. PubMed ID: 6812366
    [Abstract] [Full Text] [Related]

  • 23. Early iron overload in beta-thalassaemia major: when to start chelation therapy?
    Fargion S, Taddei MT, Gabutti V, Piga A, Di Palma A, Capra L, Fontanelli G, Avanzini A.
    Arch Dis Child; 1982 Dec; 57(12):929-33. PubMed ID: 7181522
    [Abstract] [Full Text] [Related]

  • 24. Model-Based Optimisation of Deferoxamine Chelation Therapy.
    Bellanti F, Del Vecchio GC, Putti MC, Cosmi C, Fotzi I, Bakshi SD, Danhof M, Della Pasqua O.
    Pharm Res; 2016 Feb; 33(2):498-509. PubMed ID: 26555666
    [Abstract] [Full Text] [Related]

  • 25. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 26. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N.
    Hematology; 2007 Dec 10; 12(6):577-85. PubMed ID: 17852442
    [Abstract] [Full Text] [Related]

  • 27. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Dec 10; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 28. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia.
    Koliakos G, Papachristou F, Koussi A, Perifanis V, Tsatra I, Souliou E, Athanasiou M.
    Clin Lab Haematol; 2003 Apr 10; 25(2):105-9. PubMed ID: 12641614
    [Abstract] [Full Text] [Related]

  • 29. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Apr 10; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 30. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A.
    Eur J Pediatr; 1981 Nov 10; 137(3):267-71. PubMed ID: 7318837
    [Abstract] [Full Text] [Related]

  • 31. Desferrioxamine and urinary zinc excretion in beta-thalassemia major.
    Uysal Z, Akar N, Kemahli S, Dincer N, Arcasoy A.
    Pediatr Hematol Oncol; 1993 Nov 10; 10(3):257-60. PubMed ID: 8217542
    [Abstract] [Full Text] [Related]

  • 32. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB, Shah FT.
    Hematol Oncol Clin North Am; 2010 Dec 10; 24(6):1109-30. PubMed ID: 21075283
    [Abstract] [Full Text] [Related]

  • 33. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Dec 10; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 34. Deferasirox.
    Stumpf JL.
    Am J Health Syst Pharm; 2007 Mar 15; 64(6):606-16. PubMed ID: 17353569
    [Abstract] [Full Text] [Related]

  • 35. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
    Kuo HT, Tsai MY, Peng CT, Wu KH.
    Hemoglobin; 2006 Mar 15; 30(2):291-9. PubMed ID: 16798654
    [Abstract] [Full Text] [Related]

  • 36. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 15; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 37. Clinical Challenges with Iron Chelation in Beta Thalassemia.
    Kwiatkowski JL.
    Hematol Oncol Clin North Am; 2023 Apr 15; 37(2):379-391. PubMed ID: 36907610
    [Abstract] [Full Text] [Related]

  • 38. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2009 Apr 15; 33(5):323-31. PubMed ID: 19814678
    [Abstract] [Full Text] [Related]

  • 39. Long-term administration of high-dose deferoxamine 2 days per week in thalassemic patients.
    Hagège I, Becker A, Kerdaffrec T, Kanfer A, Girot R.
    Eur J Haematol; 2001 Oct 15; 67(4):230-1. PubMed ID: 11860443
    [Abstract] [Full Text] [Related]

  • 40. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Pharmacoeconomics; 2007 Oct 15; 25(4):329-42. PubMed ID: 17402805
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.